Tami Tillotson Martin Sells 8,100 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Stock

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) VP Tami Tillotson Martin sold 8,100 shares of the company’s stock in a transaction that occurred on Wednesday, August 30th. The shares were sold at an average price of $32.00, for a total value of $259,200.00. Following the completion of the sale, the vice president now owns 85,249 shares in the company, valued at approximately $2,727,968. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Tami Tillotson Martin also recently made the following trade(s):

• On Friday, August 25th, Tami Tillotson Martin sold 5,135 shares of Supernus Pharmaceuticals stock. The shares were sold at an average price of $31.59, for a total value of $162,214.65.

Supernus Pharmaceuticals Trading Up 2.0 %

Shares of NASDAQ SUPN opened at $32.49 on Friday. The firm has a market cap of $1.77 billion, a P/E ratio of 44.51 and a beta of 1.01. Supernus Pharmaceuticals, Inc. has a 1-year low of $29.06 and a 1-year high of $42.09. The business’s 50 day moving average is $30.86 and its 200-day moving average is $34.25.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.02) earnings per share for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.25). The firm had revenue of $135.56 million for the quarter, compared to the consensus estimate of $143.63 million. Supernus Pharmaceuticals had a return on equity of 4.86% and a net margin of 6.84%. Supernus Pharmaceuticals’s revenue for the quarter was down 20.3% on a year-over-year basis. During the same quarter last year, the business posted $0.14 EPS. Analysts forecast that Supernus Pharmaceuticals, Inc. will post 1.53 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on SUPN shares. Piper Sandler dropped their price objective on Supernus Pharmaceuticals from $46.00 to $43.00 in a research note on Wednesday, July 26th. StockNews.com lowered Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, August 16th. Finally, TheStreet lowered Supernus Pharmaceuticals from a “b+” rating to a “c+” rating in a research note on Friday, May 12th.

Institutional Investors Weigh In On Supernus Pharmaceuticals

Large investors have recently added to or reduced their stakes in the stock. Glass Jacobson Investment Advisors llc acquired a new stake in Supernus Pharmaceuticals during the second quarter worth approximately $30,000. Public Employees Retirement System of Ohio grew its position in Supernus Pharmaceuticals by 41.6% during the third quarter. Public Employees Retirement System of Ohio now owns 1,253 shares of the specialty pharmaceutical company’s stock worth $42,000 after buying an additional 368 shares in the last quarter. Mendota Financial Group LLC acquired a new stake in Supernus Pharmaceuticals during the first quarter worth approximately $46,000. Tower Research Capital LLC TRC grew its position in Supernus Pharmaceuticals by 389.7% during the first quarter. Tower Research Capital LLC TRC now owns 1,327 shares of the specialty pharmaceutical company’s stock worth $48,000 after buying an additional 1,056 shares in the last quarter. Finally, Group One Trading L.P. grew its position in Supernus Pharmaceuticals by 103.6% during the fourth quarter. Group One Trading L.P. now owns 1,499 shares of the specialty pharmaceutical company’s stock worth $53,000 after buying an additional 43,303 shares in the last quarter.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age.